Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Listing Proposed Rule Would Add Burdens To Code System – Industry

This article was originally published in The Tan Sheet

Executive Summary

If FDA starts assigning companies National Drug Code numbers as it has proposed, it would "undo needed flexibility" for industry, the Consumer Healthcare Products Association says

You may also be interested in...

CHPA Questions Timetable, Export Requirements In FDA’s NDC Proposal

An FDA proposed rule for changes to the National Drug Code system does not adequately distinguish regulatory requirements for export-only and imported-for-export products, the Consumer Health Products Association says Jan. 26

FDA To Hold Drug Code Meeting, Extends Proposed Rule Comment Deadline

FDA has planned a public meeting to discuss proposed changes to the National Drug Code (NDC) system in the agency's proposed rule on "Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs," according to a notice published in the Oct. 31 Federal Register

Establishment registration proposed rule

CHPA is concerned FDA's proposed rule on "Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs" would make "substantial changes" to the OTC monograph system, the group notes in an Oct. 12 letter requesting an extension of the comment period for the proposal, which appeared in the Aug. 29 Federal Register. CHPA asks the agency to extend the comment period by 60 days to Jan. 26. "It is clear that the detail of the proposed rule and the numerous complex scenarios it may create for entities along the supply chain, the need to examine carefully the information contained in the proposed rule" and its impact on member companies will require more time to form a response, CHPA says. Some of the changes that apply to all pharmaceutical manufacturers "may be felt more acutely" by the OTC industry, particularly the effect of assigning a National Drug Code to manufacturers of monograph drugs, the group says...

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts